Patent Thicket Remedies
Yesterday, the Initiative for Medicines, Access, and Knowledge I-MAK took an important step by proposing six policy solutions to address patent thickets that block generic and biosimilar drug competition.
The Economics of “Delinking” PBM Compensation
Pharmacy benefit managers (PBMs) are a popular Congressional target of late.
Unintended Consequences of Limiting PBMs
As Congress stumbles toward a government shutdown, health policy legislation continues to simmer in the background.
Humira Competitors Don’t Guarantee Lower Patient Drug Costs
“The launches this month are “more of an inflection point in the market compared to what we saw in January when Amjevita came to market,” said Alex Brill.
The State of Biosimilars: What to Watch
Now that biosimilar versions of Humira are starting to arrive, what happens next? Will this finally prove the case that biosimilars can deliver on big health care savings?
- Patent Thicket Remedies
- Don’t Mix US Tax Administration Policy with the Israel-Hamas Conflict
- The Economics of “Delinking” PBM Compensation
- The Supreme Court Should Leave the Tax Code Alone
- Implications of Cannabis Legalization for the US Federal Budget
- Amicus Brief in Moore v. United States
- Biosimilars – Keys to Success in the Pharmacy Benefit
- New MGA White Paper Examines Consequences of Regulatory Uncertainty for Employee Ownership
- MGA Releases White Paper on Role of PBMs in US Drug Pricing Debate
- Unintended Consequences of Limiting PBMs
